BerryC., HannenhalliS., LeipzigJ., and BushmanF.D. (2006). Selection of target sites for mobile DNA integration in the human genome. PLoS Comput. Biol., 2, e157.
3.
BerryC.C., GilletN.A., MelamedA., et al. (2012). Estimating abundances of retroviral insertion sites from DNA fragment length data. Bioinformatics, 28, 755–762.
4.
BerryC.C., OcwiejaK.E., MalaniN., and BushmanF.D. (2014). Comparing DNA integration site clusters with scan statistics. Bioinformatics [Epub ahead of print]; doi: 10.1093/bioinformatics/btu035.
5.
BorY.C., BushmanF., and OrgelL. (1995). In Vitro integration of human immunodeficiency virus type 1 cDNA into targets containing protein-induced bends. Proc. Natl. Acad. Sci. USA, 92, 10334–10338.
6.
BradyT., LeeY.N., RonenK., et al. (2009). Integration target site selection by a resurrected human endogenous retrovirus. Genes Dev., 23, 633–642.
7.
BradyT., RothS.L., MalaniN., et al. (2011). A method to sequence and quantify DNA integration for monitoring outcome in gene therapy. Nucleic Acids Res., 39, e72.
8.
BushmanF.D. (1994). Tethering human immunodeficiency virus 1 integrase to a DNA site directs integration to nearby sequences. Proc. Natl. Acad. Sci. USA, 91, 9233–9237.
9.
BushmanF.D. (2001). Lateral DNA Transfer: Mechanisms and Consequences (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).
10.
BushmanF.D. (2007). Retroviral integration and human gene therapy. J. Clin. Invest., 117, 2083–2086.
11.
BushmanF.D., and PtashneM. (1986). Activation of transcription by the bacteriophage 434 repressor. Proc. Natl. Acad. Sci. USA, 83, 9353–9357.
12.
BushmanF.D., and PtashneM. (1988). Turning lambda Cro into a transcriptional activator. Cell, 54, 191–197.
13.
BushmanF.D., and WangB. (1994). Rous sarcoma virus integrase protein: mapping functions for catalysis and substrate binding. J. Virol., 68, 2215–2223.
14.
BushmanF.D., AndersonJ.E., HarrisonS.C., and PtashneM. (1985). Ethylation interference and X-ray crystallography identify similar interactions between 434 repressor and operator. Nature, 316, 651–653.
15.
BushmanF.D., ShangC., and PtashneM. (1989). A single glutamic acid residue plays a key role in the transcriptional activation function of lambda repressor. Cell, 58, 1163–1171.
16.
BushmanF.D., FujiwaraT., and CraigieR. (1990). Retroviral DNA integration directed by HIV integration protein in vitro. Science, 249, 1555–1558.
17.
BushmanF.D., HoffmannC., RonenK., et al. (2008). Massively parallel pyrosequencing in HIV research. AIDS, 22, 1411–1415.
18.
CarteauS., GorelickR., and BushmanF.D. (1999). Coupled integration of human immunodeficiency virus cDNA ends by purified integrase in vitro: stimulation by the viral nucleocapsid protein. J. Virol., 73, 6670–6679.
19.
CartierN., Hacein-Bey-AbinaS., BartholomaeC.C., et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science, 326, 818–823.
20.
Cavazzana-CalvoM., Hacein-BeyS., De Saint BasileG., et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science, 288, 669–672.
21.
Cavazzana-CalvoM., PayenE., NegreO., et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature, 467, 318–322.
22.
CharlsonE.S., DiamondJ.M., BittingerK., et al. (2012). Lung-enriched organisms and aberrant bacterial and fungal respiratory microbiota after lung transplant. Am. J. Respir. Crit. Care Med., 186, 536–545.
23.
CherepanovP., MaertensG., ProostP., et al. (2003). HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J. Biol. Chem., 278, 372–381.
24.
CiuffiA., and BushmanF.D. (2006). Retroviral DNA integration: HIV and the role of LEDGF/p75. Trends Genet., 22, 388–395.
25.
CiuffiA., LlanoM., PoeschlaE., et al. (2005). A role for LEDGF/p75 in targeting HIV DNA integration. Nat. Med., 11, 1287–1289.
26.
CiuffiA., RonenK., BradyT., et al. (2009). Methods for integration site distribution analyses in animal cell genomes. Methods, 47, 261–268.
27.
CraigieR., and MizuuchiK. (1985). Mechanism of transposition of bacteriophage Mu: structure of a transposition intermediate. Cell, 41, 867–876.
28.
CraigieR., and MizuuchiK. (1987). Joining of Mu to target DNA can be uncoupled from cleavage at the end of Mu. Cell, 51, 493–501.
29.
CraigieR., MizuuchiM., and MizuuchiK. (1984). Site-specific recognition of the bacteriophage Mu ends by the Mu A protein. Cell, 39, 387–394.
30.
CraigieR., Arndt-JovinD.J., and MizuuchiK. (1985). A defined system for the DNA strand-transfer reaction at the initiation of bacteriophage Mu transposition: protein and DNA substrate requirements. Proc. Natl. Acad. Sci. USA, 82, 7570–7574.
31.
CraigieR., FujiwaraT., and BushmanF. (1990). The IN protein of Moloney murine leukemia virus processes the viral DNA ends and accomplishes their integration in vitro. Cell, 62, 829–837.
32.
De RijckJ., De KogelC., DemeulemeesterJ., et al. (2013). The BET family of proteins targets moloney murine leukemia virus integration near transcription start sites. Cell Rep., 5, 886–894.
33.
DiamondT.L., and BushmanF.D. (2005). Division of labor within human immunodeficiency virus integrase complexes: determinants of catalysis and target DNA capture. J. Virol., 79, 15376–15387.
34.
DiamondT.L., and BushmanF.D. (2006). Role of metal ions in catalysis by HIV integrase analyzed using a quantitative PCR disintegration assay. Nucleic Acids Res., 34, 6116–6125.
35.
EngelmanA., MizuuchiK., and CraigieR. (1991). HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell, 67, 1211–1221.
36.
FarnetC., LipfordR., WangB., and BushmanF.D. (1996). Differential inhibition of HIV-1 preintegration complexes and purified integrase protein by small molecules. Proc. Natl. Acad. Sci. USA, 93, 9742–9747.
37.
GaoK., WongS., and BushmanF. (2004). Metal binding by the D,DX35E motif of human immunodeficiency virus type 1 integrase: selective rescue of Cys substitutions by Mn2+ in vitro. J. Virol., 78, 6715–6722.
38.
GijsbersR., RonenK., VetsS., et al. (2010). LEDGF hybrids efficiently retarget lentiviral integration into heterochromatin. Mol. Ther., 18, 552–560.
39.
GruppS.A., KalosM., BarrettD., et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med., 368, 1509–1518.
40.
GuptaK., DiamondT., HwangY., et al. (2010). Structural properties of HIV integrase. Lens epithelium-derived growth factor oligomers. J. Biol. Chem., 285, 20303–20315.
41.
GuptaS.S., MaetzigT., MaertensG.N., et al. (2013). Bromo- and extraterminal domain chromatin regulators serve as cofactors for murine leukemia virus integration. J. Virol., 87, 12721–12736.
42.
Hacein-Bey-AbinaS., Von KalleC., SchmidtM., et al. (2003a). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 348, 255–256.
43.
Hacein-Bey-AbinaS., Von KalleC., SchmidtM., et al. (2003b). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302, 415–419.
44.
Hacein-Bey-AbinaS., GarrigueA., WangG.P., et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest., 118, 3132–3142.
45.
Hacein-Bey-AbinaS., HauerJ., LimA., et al. (2010). Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 363, 355–364.
46.
HildebrandtM.A., HoffmannC., Sherrill-MixS.A., et al. (2009). High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology, 137, 1716–1724.e1–2.
47.
HoffmannC., MinkahN., LeipzigJ., et al. (2007). DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res., 35, e91.
48.
HoffmannC., HillD.A., MinkahN., et al. (2009). Community-wide response of the gut microbiota to enteropathogenic Citrobacter rodentium infection revealed by deep sequencing. Infect. Immun., 77, 4668–4678.
49.
HoweS.J., MansourM.R., SchwarzwaelderK., et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest., 118, 3143–3150.
50.
KaeppelC., BeattieS.G., FronzaR., et al. (2013). A largely random AAV integration profile after LPLD gene therapy. Nat. Med., 19, 889–891.
51.
LevineB.L., HumeauL.M., BoyerJ., et al. (2006). Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. USA, 103, 17372–17377.
52.
LiH., HaurigotV., DoyonY., et al. (2011a). In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature, 475, 217–221.
53.
LiH., MalaniN., HamiltonS.R., et al. (2011b). Assessing the potential for AAV vector genotoxicity in a murine model. Blood, 117, 3311–3319.
54.
MaguireA.M., SimonelliF., PierceE.A., et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med., 358, 2240–2248.
55.
MarshallH.M., RonenK., BerryC., et al. (2007). Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting. Plos One, 2, e1340.
56.
McKennaP., HoffmannC., MinkahN., et al. (2008). The macaque gut microbiome in health, lentiviral infection, and chronic enterocolitis. PLoS Pathogens, 4, e20.
57.
MillerM.D., WangB., and BushmanF.D. (1995). HIV-1 preintegration complexes containing discontinuous plus strands are competent to integrate in vitro. J. Virol., 69, 3938–3944.
58.
MinotS., GrunbergS., WuG.D., et al. (2012). Hypervariable loci in the human gut virome. Proc. Natl. Acad. Sci. USA, 109, 3962–3966.
59.
MinotS., BrysonA., ChehoudC., et al. (2013). Rapid evolution of the human gut virome. Proc. Natl. Acad. Sci. USA, 110, 12450–12455.
60.
MitchellR.S., BeitzelB.F., SchroderA.R.W., et al. (2004). Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol., 2, 1127–1137.
61.
MizuuchiK. (1983). In vitro transposition of bacteriophage Mu: a bioochemical approach to a novel replication reaction. Cell, 35, 785–794.
62.
MizuuchiK., and AdzumaK. (1991). Inversion of the phosphate chirality at the target site of Mu DNA strand transfer: evidence for a one-step transesterification mechanism. Cell, 66, 129–140.
63.
NathwaniA.C., TuddenhamE.G., RangarajanS., et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med., 365, 2357–2365.
64.
PeterfreundG.L., VandivierL.E., SinhaR., et al. (2012). Succession in the gut microbiome following antibiotic and antibody therapies for clostridium difficile. PLoS One, 7, e46966.
65.
PrussD., BushmanF.D., and WolffeA.P. (1994a). Human immunodeficiency virus integrase directs integration to sites of severe DNA distortion within the nucleosome core. Proc. Natl. Acad. Sci. USA, 91, 5913–5917.
66.
PrussD., ReevesR., BushmanF.D., and WolffeA.P. (1994b). The influence of DNA and nucleosome structure on integration events directed by HIV integrase. J. Biol. Chem., 269, 25031–25041.
67.
PtashneM. (1967a). Isolation of the lambda phage repressor. Proc. Natl. Acad. Sci. USA, 57, 306–313.
68.
PtashneM. (1967b). Specific binding of the lambda phage repressor to lambda DNA. Nature, 214, 232–234.
69.
PtashneM. (1986). A Genetic Switch (Cell and Blackwell Scientific Press, Cambridge, Massachusetts).
70.
RobinsH.S., CampregherP.V., SrivastavaS.K., et al. (2009). Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood, 114, 4099–4107.
71.
RobinsH.S., SrivastavaS.K., CampregherP.V., et al. (2010). Overlap and effective size of the human CD8+ T cell receptor repertoire. Sci. Transl. Med., 2, 47ra64.
72.
SchroderA.R.W., ShinnP., ChenH.M., et al. (2002). HIV-1 integration in the human genome favors active genes and local hotspots. Cell, 110, 521–529.
73.
SharmaA., LarueR.C., PlumbM.R., et al. (2013). BET proteins promote efficient murine leukemia virus integration at transcription start sites. Proc. Natl. Acad. Sci. USA, 110, 12036–12041.
74.
ShunM.C., RaghavendraN.K., VandegraaffN., et al. (2007). LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev., 21, 1767–1778.
75.
SonnenbergG.F., MonticelliL.A., AlenghatT., et al. (2012). Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science, 336, 1321–1325.
76.
SummaV., PetrocchiA., BonelliF., et al. (2008). Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem., 51, 5843–5855.
77.
TebasP., SteinD., TangW.W., et al. (2014). Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med., 370, 901–910.
WangG.P., CiuffiA., LeipzigJ., et al. (2007). HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res., 17, 1186–1194.
80.
WangG.P., GarrigueA., CiuffiA., et al. (2008). DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer. Nucleic Acids Res., 36, e49.
81.
WangG.P., LevineB.L., BinderG.K., et al. (2009). Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells. Mol. Ther., 17, 844–850.
82.
WangG.P., BerryC.C., MalaniN., et al. (2010). Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. Blood, 115, 4356–4366.
83.
WuX., LiY., CriseB., and BurgessS.M. (2003). Transcription start regions in the human genome are favored targets for MLV integration. Science, 300, 1749–1751.
84.
WuG.D., ChenJ., HoffmannC., et al. (2011). Linking long-term dietary patterns with gut microbial enterotypes. Science, 334, 105–108.
